ACTRN12622000883718
Withdrawn
Phase 2
Brain Activity Effects of Psychedelic Medicines in Healthy Volunteers
Transcranial Magnetic Stimulation Clinics Australia0 sites200 target enrollmentJune 22, 2022
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Depression
- Sponsor
- Transcranial Magnetic Stimulation Clinics Australia
- Enrollment
- 200
- Status
- Withdrawn
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Participants can be included if they are between the ages of 21 and 70, and voluntarily consent to participate after demonstrating competence to consent following discussion with one of the study researchers. Additional inclusion criteria will be:
- •\-Participants must be able to swallow capsules.
- •\-If of childbearing potential, agree to practice an effective means of birth control throughout the duration of the study.
- •\-Participants must have an identified support person and agree to be accompanied home by that person following dosing be in the presence of that person until the next day.
- •\-Agree to not operate a vehicle for at least 48 hours after initial drug administration. Participants must have transportation available after the Experimental Session and through the following day. Participants will also be warned that the substances will be potentially detectable in roadside drug tests for a number of days after ingestion.
- •\-Must provide a contact (relative, spouse, close friend, or other caregiver) who is willing and able to be reached by the investigator in the event of an emergency or if the participant is unreachable.
- •\-Must agree to inform the investigator within 48 hours if any medical conditions occur or medical procedures are planned.
- •\-Are proficient in speaking and reading English.
- •\- Have completed a Certificate in Psychedelic\-Assisted Therapies course.
Exclusion Criteria
- •\-Participants who are not able to give adequate informed consent.
- •\-Participants will be excluded if they are pregnant or lactating, have a history of neurological or mental illness or substance abuse or dependence. Participants will also be excluded if taking medication or drugs known to alter brain activity or have a history of seizures.
- •\-Have any of the following cardiovascular conditions: uncontrolled hypertension, coronary artery disease, congenital long QT syndrome, cardiac hypertrophy, cardiac ischemia, congestive heart failure, myocardial infarction, tachycardia, artificial heart valve, a clinically significant screening ECG abnormality, or any other significant cardiovascular condition.
- •\-Participants who are older than 40 years with a positive family history (in a first degree relative) of coronary heart disease and/or presenting substantive risk factors for cardiovascular disease as determined judged by a study doctor.
- •\-Have a history of ventricular arrhythmia at any time, other than occasional premature ventricular contractions (PVCs) in the absence of ischemic heart disease.
- •\-Have Wolff\-Parkinson\-White syndrome or any other accessory pathway that has not been successfully eliminated by ablation.
- •\-Moderate to severe previous or current head injury/Traumatic Brain Injury (TBI).
- •\-Have a history of stroke or Transient Ischemic Attack (TIA).
- •\-Have moderate to severe hepatic impairment.
- •\-Have epilepsy.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
egative effect of use of psychotropic drugs on psychiatric symptoms, and cognitive and physical function in elderly:prospective observational study among hospitalized patients.Psychiatric symptoms and decline of cognitive and physical functionJPRN-UMIN000004448Ishikawa Prefectural Takamatsu Hospital100
Active, not recruiting
Phase 3
To Study the Effect of Plant Formulation on sleep in Patients with Depression.Health Condition 1: null- Depressive symptoms with cognitive impairment, Sleep DisturbancesCTRI/2016/02/006681Interdisciplinary Institute of Indian System of Medicine University Building Fourth Floor60
Recruiting
Not Applicable
ong-term effects of psychotropic medication on the developing brain. A cohort study based on medical prescription databijwerkingen van medicijnenADHDMDD and anxietydisorders10042258NL-OMON36448Radiologie, Div I150
Not yet recruiting
Not Applicable
Sub(acute) Profiling of 2C-B Versus PsilocybiNL-OMON28125Maastricht University18
Completed
Not Applicable
Sub(acute) Neuropsychopharmacological Profiling of 2C-B vs Psilocybindrug effects, drug metabolitesNot applicableNL-OMON50024niversiteit Maastricht24